|
|
|
| Application of Urine MA Combined with Serum TRF α1-MG and Cystatin C in the Diagnosis of Early Kidney Injury of Diabetes Mellitus |
| WANG Tao, GAO Zhiqi, GAO Zhirong, et al |
| Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China |
|
|
|
|
Abstract Objective: To explore the application value of urine microalbumin (MA) combined with serum transferrin (TRF), α1-microglobulin (α1-MG) and cystatin C in the diagnosis of early kidney injury of diabetes mellitus. Methods: 122 patients with diabetes mellitus hospitalized between October 2018 and January 2020 were selected and divided into group A (54 case with early kidney injury) group B (68 cases without early kidney injury). Fifty healthy people who completed physical examination in the same period were enrolled as control group (group C). The middle segment urine of all subjects was collected to measure the urine MA level, and venous blood was collected to determine serum TRF, α1-MG and cystatin C levels. The positive detection rates of above indexes were compared among groups. The diagnostic efficiency of all indexes for early kidney injury of diabetes mellitus was analyzed by ROC curves. Results: There were significant differences in urine MA, serum TRF, serum α1-MG, serum cystatin C levels and positive detection rate among groups A, B and C (F=229.053, P＜0.001; F=76.828, P＜0.001; F=87.632, P＜0.001; F=47.151, P＜0.001;χ2=91.652, P＜0.001;χ2=69.050, P＜0.001;χ2=75.260, P＜0.001;χ2=78.732, P＜0.001). The sensitivities and specificities of urine MA, serum TRF, α1-MG and cystatin C for diagnosis of early kidney injury of diabetes mellitus were (95.40%, 81.50%, 75.40%, 81.50%) and (80.70%, 66.70%, 87.70%, 89.50%), respectively. The sensitivity and specificity of their combined diagnosis were 96.92% and 49.12% (AUC=0.900, 95%CI=0.846-0.954). Conclusion: The combined detection of urine MA, serum TRF, α1-MG and cystatin C is of high diagnostic value and high accuracy for early kidney injury of diabetes mellitus, which is of great significance for early screening and prevention of diabetic nephropathy.
|
|
|
|
|
|
[1] Ioannou K.Diabetic nephropathy: is it always there assumptions,weaknesses and pitfalls in the diagnosis[J].Hormones,2017,16(4):351~361.
[2] Papadopoulou N,Chrousos GP,Kanaka C.Diabetic nephropathy in type 1 diabetes: a review of early natural history,pathogenesis and diagnosis[J].Diabetes Metab Res Rev,2017,33(2):135~140.
[3] Papadopoulou N,Paschou SA,Marketos N,et al.Diabetic nephropathy in type 1 diabetes[J].Minerva Med,2018,109(3):218~228.
[4] Papadopoulou N,Kanaka C,Marketos N,et al.Biomarkers of diabetic nephropathy: a 2017 update[J].Crit Rev Clin Lab Sci,2017,54(5):326~342.
[5] 汪晓妹.血清胱抑素C、尿微量白蛋白/肌酐值测定在老年2型糖尿病早期肾功能损伤中的意义[J].中国实验诊断学,2017,21(12):2151~2153.
[6] American Diabetes Association.Classification and diagnosis of diabetes: standards of medical care in diabetes-2018[J].Diabetes Care,2018,41(1):13~27.
[7] Qi C,Mao X,Zhang Z,Wu H.Classification and differential diagnosis of diabetic nephropathy[J].Diabetes Res,2017,20(5):137~138.
[8] Meza Letelier CE,San Martin Ojeda CA,Ruiz Provoste JJ,et al.Pathophysiology of diabetic nephropathy: a literature review[J].Medwave,2017,17(1):6839.
[9] 李申,刘志红.糖尿病肾病肾小管损伤机制[J].肾脏病与透析肾移植杂志,2018,27(3):265~268.
[10] Xiong Y,Zhou L.The signaling of cellular senescence in diabetic nephropathy[J].Oxid Med Cell Longev,2019,10(3):5629.
[11] Kishore L,Kaur N,Singh R.Distinct biomarkers for early diagnosis of diabetic nephropathy[J].Curr Diabetes Rev,2017,13(6):598~605.
[12] 潘玥,金晶,何泳,等.血清同型半胱氨酸和尿液微量白蛋白水平在2型糖尿病诊治中的临床价值研究[J].标记免疫分析与临床,2019,26(5):813~814.
[13] Zhang D,Ye S,Pan T.The role of serum and urinary biomarkers in the diagnosis of early diabetic nephropathy in patients with type 2 diabetes[J].Peer,2019,11(7):7079.
[14] 陈爱珍,孙秀丽,吴红梅,等.胱抑素C、α1微球蛋白检测在继发性肾病中的临床意义[J].湖南中医药大学学报,2018,10(1):66~67. |
|
|
|
2021, Vol. 27 
